Clinical Guides
Oral Anticoagulation
A clinically focused, India-adapted guide to selecting, starting, monitoring, interrupting and reversing oral anticoagulation for atrial fibrillation, venous thromboembolism and other validated indications.
MedNext Academy | 13 min read
Oral Anticoagulation
A clinically focused, India-adapted guide to selecting, starting, monitoring, interrupting and reversing oral anticoagulation for atrial fibrillation, venous thromboembolism and other validated indications.
Summary
Oral anticoagulation prevents or treats fibrin-rich thromboembolism; it does not treat every vascular event and should never be started merely because a D-dimer is raised. The first clinical task is to name the indication: prevention of cardioembolic stroke in atrial fibrillation, treatment and secondary prevention of venous thromboembolism, prevention of embolism from a mechanical valve, or a narrower specialist indication. The second task is to estimate the untreated thrombotic risk and the modifiable and non-modifiable bleeding risks. The third is to choose a vitamin K antagonist, usually warfarin, or a direct-acting oral anticoagulant (DOAC) only after checking valve status, renal and hepatic function, pregnancy potential, weight, interacting medicines, affordability, adherence and access to monitoring. DOACs are generally preferred for eligible atrial fibrillation and are convenient because routine INR testing is unnecessary; they are not interchangeable with warfarin in mechanical prosthetic valves and are unsuitable in several high-risk clinical states. Warfarin remains valuable when its indication is strong and INR systems are reliable. Every prescription needs an indication, intended duration, dose rationale, review date, emergency bleeding plan and patient-held alert information. Temporary interruption, reversal and resumption are separate decisions driven by bleeding severity, the drug's pharmacology and the continuing thrombotic indication. This guide supports structured learning, not patient-specific prescribing.
How Common Is It?
The conditions requiring anticoagulation are common even though reliable India-wide prescribing denominators are incomplete. Atrial fibrillation becomes markedly more frequent with age and may first appear after stroke, heart failure, infection or surgery. Its embolic risk is highly heterogeneous: a young person without additional risk factors has a very different absolute benefit from anticoagulation than an older person with hypertension, diabetes or previous stroke. Venous thromboembolism includes deep-vein thrombosis and pulmonary embolism, arising after surgery, immobility, pregnancy, oestrogen exposure or cancer, but it may also be unprovoked. Hospital estimates miss events treated outside large centres and events never confirmed by imaging. Mechanical valve recipients form a smaller but particularly high-consequence population because interruption or inadequate anticoagulation can cause valve thrombosis or systemic embolism. India adds substantial variation in access to ECG monitoring, compression ultrasonography, CT pulmonary angiography, INR testing and specialist follow-up. The prevalence of an indication must therefore not become a shortcut to treatment. A clinician should confirm the relevant syndrome and estimate individual benefit. Population statistics also cannot determine duration: a provoked VTE after a resolved transient factor, an unprovoked proximal DVT, active-cancer thrombosis and permanent AF have different recurrence trajectories. Apparent underuse may reflect access barriers, but apparent overuse occurs when aspirin, anticoagulants or combinations continue without a documented indication or stop date.
Risk Factors
Thrombotic risk and anticoagulant-associated bleeding risk must be assessed in parallel. In atrial fibrillation, prior stroke or systemic embolism, older age, heart failure, hypertension, diabetes and vascular disease increase embolic risk; use a validated score within the chosen guideline and then apply clinical judgement. Female sex is a modifier rather than an isolated reason to anticoagulate. For VTE, distinguish major transient factors such as recent surgery or immobilisation, minor or persistent factors, active cancer, antiphospholipid syndrome, pregnancy, previous VTE and an apparently unprovoked event. Recurrent thrombosis while apparently treated raises adherence, interaction, absorption, dosing and diagnostic questions before it is labelled drug failure. Bleeding risk rises with previous major bleeding, uncontrolled hypertension, renal or hepatic dysfunction, thrombocytopenia, anaemia, frailty, heavy alcohol use, active gastrointestinal lesions and concurrent antiplatelets, NSAIDs or other interacting drugs. A bleeding score helps expose correctable hazards but is not an automatic veto against treatment. Falls alone rarely erase a strong stroke-prevention benefit; investigate why the person falls and reduce that risk. Warfarin instability is promoted by inconsistent dosing, acute illness, dietary change, alcohol, antibiotics and poor access to INR testing. DOAC exposure changes with renal clearance, body size and P-glycoprotein or CYP3A4 modulators. Pregnancy, planned conception and breastfeeding demand a separate pathway. Record social risks too: cost-driven missed doses, fragmented prescriptions, inability to reach laboratories and low health literacy can be as important as a laboratory value.
Diagnosis
History
Confirm why anticoagulation is being considered and whether the diagnosis is established. For atrial fibrillation, document ECG evidence, pattern, valve history, previous stroke or bleeding and each component of thrombotic and bleeding assessment. For suspected VTE, elicit symptom onset, provoking factors, previous events, cancer features, pregnancy and alternative diagnoses; apply a validated diagnostic pathway rather than treating an isolated D-dimer. Ask specifically about melaena, haematemesis, haematuria, heavy menstrual bleeding, epistaxis, falls, alcohol, all prescribed and non-prescribed medicines, adherence, last dose and upcoming procedures.
Examination
Assess haemodynamic stability, oxygenation, pallor, bruising and evidence of active or occult bleeding. Examine for an irregular pulse, heart failure, valvular disease, unilateral leg swelling, pulmonary compromise, chronic liver disease and focal neurology. A new severe headache, abdominal tenderness or neurological deficit in an anticoagulated person may represent critical-site bleeding even without external blood loss.
Investigations
Before starting, obtain full blood count, creatinine with Cockcroft-Gault creatinine clearance for DOAC dosing, liver profile, PT/INR and APTT; perform pregnancy testing when relevant. Use ECG and echocardiography where AF or valve disease is involved and objective imaging for VTE. PT or APTT cannot quantify every DOAC reliably. For warfarin, establish the indication-specific target INR and a monitoring plan. Falling haemoglobin, platelets or renal function during therapy demands explanation, not merely dose renewal.
Differential Diagnosis
Before prescribing, separate thromboembolic disease from mimics and distinguish conditions requiring anticoagulation from those requiring antiplatelet therapy or neither. An irregular pulse may be ectopy rather than atrial fibrillation; ECG confirmation is essential. Unilateral leg swelling may be cellulitis, ruptured Baker cyst, trauma, venous insufficiency or lymphoedema. Breathlessness and pleuritic pain may reflect pneumonia, pneumothorax, acute coronary syndrome, pericarditis or heart failure. A raised D-dimer is non-specific and occurs with age, inflammation, pregnancy, malignancy and recent surgery. Ischaemic stroke may be cardioembolic, large-artery atherosclerotic, small-vessel or another mechanism; empiric anticoagulation for an embolic stroke of uncertain source can cause harm. Mechanical prosthetic valves must be distinguished from most native valve lesions and bioprosthetic valves because the evidence and permitted drug differ. Antiphospholipid syndrome, particularly a triple-positive high-risk phenotype, changes drug selection. In an anticoagulated person with falling haemoglobin, consider gastrointestinal or genitourinary bleeding, retroperitoneal haemorrhage, menstruation, haemolysis and marrow disease. Thrombocytopenia may arise from infection, medicines, liver disease or heparin-induced thrombocytopenia rather than consumption from bleeding. An unexpectedly high INR prompts review of dosing, diet, acute illness, alcohol and interacting medicines; an apparently normal INR in a DOAC user neither proves absence of drug nor excludes clinically relevant anticoagulation. Finally, distinguish treatment failure from non-adherence, underdosing, interruption, malabsorption, interaction and an incorrect original diagnosis.
Management
Start with a written indication-and-duration decision. In eligible atrial fibrillation, offer a DOAC when stroke risk justifies therapy and there is no mechanical valve, clinically significant mitral stenosis or other contraindication; warfarin is the alternative when a DOAC is unsuitable and is required for mechanical valves. In confirmed proximal DVT or pulmonary embolism, treat for at least three months, using an approved regimen. Apixaban and rivaroxaban have oral initial-treatment regimens, whereas dabigatran and edoxaban follow initial parenteral anticoagulation; never assume identical initiation or dose-reduction rules. At about three months, classify the event as provoked, unprovoked, cancer-associated or persistent-risk and balance recurrence against bleeding. A resolved major transient factor may support stopping; unprovoked disease with acceptable bleeding risk often supports extended therapy. Mechanical-valve treatment and peri-pregnancy care require specialist protocols. Correct hypertension, anaemia, alcohol excess and avoidable NSAID or antiplatelet exposure. Give an alert card and teach adherence, missed-dose rules specific to the prescribed product, bleeding symptoms and the danger of unsupervised cessation. Review at least annually and sooner with frailty, intercurrent illness, weight change or renal decline. Peri-procedure planning begins with procedural bleeding risk, renal function, last dose and thrombotic indication. Many minor procedures need no or minimal interruption. DOACs usually require timed cessation without heparin bridging; warfarin bridging is reserved for selected high-thrombotic-risk situations, not used automatically. After interruption or bleeding, restart when haemostasis is secure and benefit again exceeds risk.
Prescribing Information
Write the generic drug, exact indication, dose, frequency, start date and intended review or stop date. DOAC doses are indication-specific; dose reduction criteria differ between AF and acute VTE and between agents. Calculate creatinine clearance using Cockcroft-Gault rather than substituting laboratory eGFR, because eGFR can overestimate function in older or low-weight patients. Check hepatic disease, platelet count, haemoglobin and interacting drugs. Strong P-glycoprotein or CYP3A4 inhibitors may increase DOAC exposure, while inducers may reduce efficacy; check the locally approved product information rather than memorising a partial interaction list. Warfarin dosing is individualised by INR. Most AF and VTE indications use a target INR range centred on 2.5, but mechanical-valve targets vary by valve and patient risk, so the specialist target must be recorded. Keep dietary vitamin K intake consistent rather than eliminating nutritious green vegetables. Recheck INR after important medicine, illness, dietary or alcohol changes. Avoid concurrent anticoagulants except during a deliberate, protocol-defined transition. Combining an anticoagulant with one or two antiplatelets markedly increases bleeding and needs a current coronary indication and explicit stop plan. In pregnancy, LMWH is generally preferred for VTE; oral agents require specialist review, and DOACs should not be used during breastfeeding under ASH guidance. For major bleeding, stop the anticoagulant, resuscitate, find and control the source, establish last intake and renal function, and activate local reversal pathways. Vitamin K plus four-factor PCC is preferred for major warfarin bleeding; idarucizumab reverses dabigatran, while andexanet alfa or PCC-based strategies may be used for factor Xa inhibitors according to indication and availability.
When to Refer
Refer urgently to emergency or specialist care for haemodynamic instability, suspected pulmonary embolism with compromise, acute limb-threatening thrombosis, new focal neurology, intracranial or other critical-site bleeding, rapidly falling haemoglobin, uncontrolled gastrointestinal bleeding or a required emergency procedure while clinically anticoagulated. Discuss mechanical prosthetic valves, moderate-to-severe mitral stenosis, pregnancy, planned conception, breastfeeding, severe renal impairment, significant hepatic synthetic dysfunction, active cancer, antiphospholipid syndrome, extreme body weight and recurrent thrombosis with an appropriate specialist. Haematology input is valuable when the indication is uncertain, thrombophilia would change management, thrombocytopenia coexists or bleeding recurs despite apparently correct treatment. Cardiology input is appropriate for complex AF stroke prevention, left atrial appendage strategies, recent coronary intervention or combined anticoagulant-antiplatelet therapy. Refer to an anticoagulation service when warfarin time in therapeutic range remains poor despite addressing adherence, illness, interactions and monitoring access. Surgical, anaesthetic, dental and prescribing teams should share one peri-procedure plan; vague instructions such as stop for a few days are unsafe. In resource-variable settings, referral may mean telephone coordination with a district specialist or transfer to a centre stocking PCC, specific antidotes, anti-Xa testing, endoscopy, interventional radiology or neurosurgery. Stable patients still need planned review when kidney function declines, falls increase, recurrent minor bleeding affects adherence or cost makes the selected regimen unsustainable. Referral is not a substitute for immediate stabilisation or withholding the next dose during a major bleed.
Red Flags
Treat suspected intracranial haemorrhage as an emergency: sudden severe headache, reduced consciousness, seizure, new weakness, speech disturbance, ataxia or head injury with neurological change needs immediate imaging and reversal assessment. Other major-bleed signals include shock, persistent tachycardia, syncope, haematemesis, melaena, large-volume rectal bleeding, severe haematuria, retroperitoneal pain, rapidly expanding haematoma, heavy uterine bleeding with instability, a haemoglobin fall of at least 2 g/dL or transfusion requirement. Do not wait for an INR in a DOAC-treated patient before beginning resuscitation and source control. Conversely, abrupt cessation can precipitate stroke, recurrent VTE or valve thrombosis; once bleeding is controlled, formally reassess when and how to restart. Thrombotic red flags despite treatment include new unilateral swelling, pleuritic chest pain, hypoxaemia, neurological deficit or symptoms of mechanical-valve obstruction. Verify the diagnosis, adherence, last doses, renal function and interactions rather than simply doubling medication. A pregnancy discovered during oral anticoagulation requires prompt specialist advice, not abrupt unsupported discontinuation. Before spinal or neuraxial procedures, anticoagulant timing is safety-critical because spinal haematoma can cause paralysis. A patient taking warfarin with an unexpectedly high INR, acute illness or a newly prescribed antibiotic needs timely review even if not yet bleeding. Any prescription combining anticoagulation, aspirin and a P2Y12 inhibitor without a recent documented coronary rationale and planned de-escalation is a preventable high-risk situation.
Indian Clinical Context
India's NLEM 2022 lists warfarin, dabigatran and parenteral anticoagulants such as heparin and enoxaparin, but formulary inclusion does not guarantee continuous local stock, affordable branded alternatives or access to reversal. Warfarin may be economically attractive yet unsafe if INR testing, dose communication and follow-up are unreliable. A DOAC may reduce laboratory visits but missed doses rapidly reduce protection because its effect wanes faster than warfarin, and monthly cost can undermine persistence. Choose the regimen the patient can obtain and take safely, not the most fashionable molecule. Document creatinine clearance in mL/min, weight, indication and dose rationale because prescriptions are often renewed across facilities. Give written instructions in the patient's preferred language and reconcile Ayurvedic, over-the-counter and pharmacy-supplied medicines; NSAIDs, antiplatelets and interacting antimicrobials may be added without the anticoagulation prescriber knowing. Diet counselling should emphasise consistency, avoiding the harmful instruction to eliminate all leafy vegetables. Create a practical INR route before discharging a warfarin user, including who receives results and changes doses. District hospitals should know where PCC, idarucizumab, factor Xa reversal, urgent endoscopy and neurosurgery are available; absence of a specific antidote makes early supportive care and transfer planning more important. Pregnancy and cancer pathways should coordinate cardiology, haematology and obstetrics or oncology. Avoid extrapolating a foreign drug licence or dose to Indian product information without checking CDSCO-approved labelling and institutional formulary. Record uncertainty honestly where Indian outcome or access data are sparse.
NMC Competency Mapping
This topic integrates General Medicine, Pharmacology, Pathology, Obstetrics and Gynaecology, Surgery and emergency-care competencies rather than belonging to a single drug list. A learner should be able to take a focused history for atrial fibrillation, VTE and bleeding; assess pulse, perfusion, venous signs and focal neurology; and select confirmatory ECG, imaging and laboratory tests. Clinical reasoning includes distinguishing cardioembolic disease from atherosclerotic platelet-driven disease, identifying provoking factors, calculating validated thrombotic and bleeding scores without allowing a score to replace judgement, and recognising when pregnancy, cancer, valve disease or organ dysfunction alters care. Rational-prescribing competence requires writing an indication-specific prescription, using Cockcroft-Gault renal function for DOAC decisions, defining INR monitoring for warfarin, checking interactions, counselling on adherence and documenting duration. Emergency competence includes initial resuscitation of major bleeding, source control, drug-specific reversal principles and safe escalation. Perioperative competence includes classifying procedural bleeding risk and coordinating interruption and resumption. Communication competence includes shared decision-making about absolute benefit and harm, alert-card education, cost and laboratory access. Assessment can use an OSCE prescription review, an AF stroke-prevention case, a provoked-versus-unprovoked VTE duration viva, interpretation of an unstable INR, and an emergency bleed scenario. The expected graduate outcome is not recall of every proprietary dose; it is a reproducible safety process that finds the correct current label and specialist protocol when a high-risk detail falls outside independent practice.
Key Exam Pearls for NEET PG
First identify the clot mechanism and indication. Anticoagulants inhibit the coagulation cascade and are central to AF-related embolic prevention and VTE; antiplatelets target platelet activation in arterial atherothrombosis. Aspirin alone is not an adequate substitute for indicated anticoagulation in AF. CHA2DS2-VASc estimates embolic risk in conventional AF pathways, while bleeding tools identify modifiable hazards rather than automatically withholding therapy. DOACs are generally preferred for eligible non-valvular AF, but mechanical prosthetic valves require a vitamin K antagonist; high-risk antiphospholipid syndrome also favours warfarin. Acute VTE regimens are not class-identical: apixaban and rivaroxaban can begin orally with an intensified phase, while dabigatran and edoxaban require initial parenteral anticoagulation. Treat proximal DVT or PE for at least three months, then reassess provocation, recurrence and bleeding. DOAC dosing uses Cockcroft-Gault creatinine clearance, not an uncritical eGFR. Routine INR testing does not measure DOAC effect, whereas warfarin requires indication-specific INR monitoring and is affected by illness, diet and interactions. Pregnancy-associated VTE is generally treated with LMWH; DOACs are avoided in pregnancy and breastfeeding. Perioperative DOAC interruption depends on renal clearance and procedural bleeding risk, and routine heparin bridging is discouraged. For life-threatening warfarin bleeding, give vitamin K with four-factor PCC; idarucizumab is specific for dabigatran, and andexanet alfa targets factor Xa inhibitors where authorised and available. Always ask the highest-yield safety questions: last dose, renal function, haemodynamic state, bleeding site and continuing thrombotic indication.
Frequently Asked Questions
Is a DOAC always safer and better than warfarin?
No. DOACs are preferred for many eligible people with atrial fibrillation or VTE because they have predictable dosing and no routine INR requirement, but suitability depends on indication, kidney and liver function, interactions, pregnancy and affordability. Mechanical prosthetic valves require a vitamin K antagonist, and warfarin may be preferable in selected antiphospholipid syndrome or severe-organ-dysfunction pathways.
Can anticoagulation be stopped before a dental procedure?
Not automatically. Many low-bleeding-risk dental procedures can proceed with continued treatment or a minimal, drug-specific adjustment plus local haemostasis. The dentist and prescriber should document the procedure, renal function, indication and last dose. Unplanned interruption can cause stroke, VTE or valve thrombosis; high-risk procedures need a coordinated plan rather than generic advice.
What monitoring is needed when routine INR is unnecessary?
A DOAC still requires clinical review. Check adherence, bleeding, haemoglobin, renal and hepatic function, weight, new medicines and whether the indication and dose remain correct. Review at least annually and more frequently with older age, frailty, intercurrent illness or renal decline. INR is not the monitoring test, but absence of INR testing does not mean absence of monitoring.
What should happen after major anticoagulant-related bleeding?
Stop further doses, resuscitate, control the bleeding source and establish the drug, last intake, renal function and relevant coagulation tests. Use drug-specific reversal for life-threatening or uncontrolled bleeding according to the local protocol. After haemostasis, reassess the original thrombotic indication; many patients need appropriately timed resumption because permanent cessation also carries serious risk.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic